Health Canada Grants Priority Review to AbbVie’s Hepatitis C Regimen

Health Canada granted priority review to AbbVie’s pan-genotypic regimen of glecaprevir and pibrentasvir for the treatment of all major chronic hepatitis C virus genotypes.

The once-daily, fixed-dose, combination regimen combines two antiviral agents, delivered as three oral tablets.

In Europe, AbbVie’s marketing authorization application for the regimen was recently validated and is now under accelerated assessment by the European Medicines Agency.